Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 365

1.

Impact of induction regimen and allogeneic hematopoietic cell transplantation on outcome in younger adults with acute myeloid leukemia with a monosomal karyotype.

Baron F, Stevens-Kroef M, Kicinski M, Meloni G, Muus P, Marie JP, Halkes CJM, Thomas X, Vrhovac R, Albano F, Lefrère F Sr, Sica S, Mancini M, Venditti A, Hagemeijer A, Jansen JH, Amadori S, de Witte T, Willemze R, Suciu S.

Haematologica. 2019 Jun;104(6):1168-1175. doi: 10.3324/haematol.2018.204826. Epub 2018 Dec 6.

2.

Cytogenetic clonal heterogeneity is not an independent prognosis factor in 15-60-year-old AML patients: results on 1291 patients included in the EORTC/GIMEMA AML-10 and AML-12 trials.

Baron F, Stevens-Kroef M, Kicinski M, Meloni G, Muus P, Marie JP, Halkes CJM, Thomas X, Vrhovac R, Specchia G, Lefrere F Sr, Sica S, Mancini M, Venditti A, Hagemeijer A, Becker H, Jansen JH, Amadori S, de Witte T, Willemze R, Suciu S.

Ann Hematol. 2018 Oct;97(10):1785-1795. doi: 10.1007/s00277-018-3396-4. Epub 2018 Jun 20.

3.

Gemtuzumab Ozogamicin Versus Best Supportive Care in Older Patients With Newly Diagnosed Acute Myeloid Leukemia Unsuitable for Intensive Chemotherapy: Results of the Randomized Phase III EORTC-GIMEMA AML-19 Trial.

Amadori S, Suciu S, Selleslag D, Aversa F, Gaidano G, Musso M, Annino L, Venditti A, Voso MT, Mazzone C, Magro D, De Fabritiis P, Muus P, Alimena G, Mancini M, Hagemeijer A, Paoloni F, Vignetti M, Fazi P, Meert L, Ramadan SM, Willemze R, de Witte T, Baron F.

J Clin Oncol. 2016 Mar 20;34(9):972-9. doi: 10.1200/JCO.2015.64.0060. Epub 2016 Jan 25.

4.

Decitabine improves progression-free survival in older high-risk MDS patients with multiple autosomal monosomies: results of a subgroup analysis of the randomized phase III study 06011 of the EORTC Leukemia Cooperative Group and German MDS Study Group.

Lübbert M, Suciu S, Hagemeijer A, Rüter B, Platzbecker U, Giagounidis A, Selleslag D, Labar B, Germing U, Salih HR, Muus P, Pflüger KH, Schaefer HE, Bogatyreva L, Aul C, de Witte T, Ganser A, Becker H, Huls G, van der Helm L, Vellenga E, Baron F, Marie JP, Wijermans PW; EORTC Leukemia Group and the German MDS Study Group.

Ann Hematol. 2016 Jan;95(2):191-9. doi: 10.1007/s00277-015-2547-0. Epub 2015 Nov 23.

5.

Comparing an Unstructured Risk Stratification to Published Guidelines in Acute Coronary Syndromes.

Beck AJ, Hagemeijer A, Tortolani B, Byrd BA, Parekh A, Datillo P, Birkhahn R.

West J Emerg Med. 2015 Sep;16(5):683-9. doi: 10.5811/westjem.2015.6.16315. Epub 2015 Oct 20.

6.

Decitabine versus best supportive care in older patients with refractory anemia with excess blasts in transformation (RAEBt) - results of a subgroup analysis of the randomized phase III study 06011 of the EORTC Leukemia Cooperative Group and German MDS Study Group (GMDSSG).

Becker H, Suciu S, Rüter BH, Platzbecker U, Giagounidis A, Selleslag D, Labar B, Germing U, Salih HR, Muus P, Pflüger KH, Hagemeijer A, Schaefer HE, Fiaccadori V, Baron F, Ganser A, Aul C, de Witte T, Wijermans PW, Lübbert M.

Ann Hematol. 2015 Dec;94(12):2003-13. doi: 10.1007/s00277-015-2489-6. Epub 2015 Sep 24.

7.

Clonal chromosomal abnormalities in Ph-negative cells in chronic myeloid leukemia: an unusual case evolving to secondary acute myeloid leukemia.

Van Obbergh F, Meeus P, Hagemeijer A, Montfort L, Vandenberghe P, Michaux L.

Cancer Genet. 2015 Mar;208(3):102-4. doi: 10.1016/j.cancergen.2014.10.007. Epub 2014 Oct 25. No abstract available.

PMID:
25475941
8.

High numbers of mobilized CD34+ cells collected in AML in first remission are associated with high relapse risk irrespective of treatment with autologous peripheral blood SCT or autologous BMT.

Hengeveld M, Suciu S, Chelgoum Y, Marie JP, Muus P, Lefrère F, Mandelli F, Pane F, Amadori S, Fioritoni G, Labar B, Baron F, Cermak J, Bourhis JH, Storti G, Fazi P, Hagemeijer A, Vignetti M, Willemze R, de Witte T.

Bone Marrow Transplant. 2015 Mar;50(3):341-7. doi: 10.1038/bmt.2014.262. Epub 2014 Nov 17.

9.

No chromosome arm unturned: in memory of Roland Berger 1934-2012.

Harrison CJ, Rowley JD, Van den Berghe H, Bernheim A, Martineau M, Gautier M, Le Coniat-Busson M, Romana S, Dastugue N, Hagemeijer A, Jonveaux P, Nguyen-Khac F, Bernard OA.

Leukemia. 2014 Feb;28(2):464-9: discussion 469. doi: 10.1038/leu.2013.340. No abstract available.

PMID:
24496283
10.

High-dose cytarabine in induction treatment improves the outcome of adult patients younger than age 46 years with acute myeloid leukemia: results of the EORTC-GIMEMA AML-12 trial.

Willemze R, Suciu S, Meloni G, Labar B, Marie JP, Halkes CJ, Muus P, Mistrik M, Amadori S, Specchia G, Fabbiano F, Nobile F, Sborgia M, Camera A, Selleslag DL, Lefrère F Sr, Magro D, Sica S, Cantore N, Beksac M, Berneman Z, Thomas X, Melillo L, Guimaraes JE, Leoni P, Luppi M, Mitra ME, Bron D, Fillet G, Marijt EW, Venditti A, Hagemeijer A, Mancini M, Jansen J, Cilloni D, Meert L, Fazi P, Vignetti M, Trisolini SM, Mandelli F, de Witte T.

J Clin Oncol. 2014 Jan 20;32(3):219-28. doi: 10.1200/JCO.2013.51.8571. Epub 2013 Dec 2.

11.

Patients with myelodysplastic syndrome and two clones with different interstitial deletions of the long arm of chromosome 5.

Verburgh E, Hagemeijer A, Delforge M, Verhoef G, Vandenberghe P.

Leuk Lymphoma. 2013 Oct;54(10):2314-7. doi: 10.3109/10428194.2013.772296. Epub 2013 Apr 4. No abstract available.

PMID:
23373968
12.

Patterns of genomic aberrations suggest that Burkitt lymphomas with complex karyotype are distinct from other aggressive B-cell lymphomas with MYC rearrangement.

Havelange V, Ameye G, Théate I, Callet-Bauchu E, Mugneret F, Michaux L, Dastugue N, Penther D, Barin C, Collonge-Rame MA, Baranger L, Terré C, Nadal N, Lippert E, Laï JL, Cabrol C, Tigaud I, Herens C, Hagemeijer A, Raphael M, Libouton JM, Poirel HA; GFCH (Groupe Francophone de Cytogénétique Hématologique).

Genes Chromosomes Cancer. 2013 Jan;52(1):81-92. doi: 10.1002/gcc.22008. Epub 2012 Sep 25.

PMID:
23012230
13.

Chronic lymphocytic leukemia and prolymphocytic leukemia with MYC translocations: a subgroup with an aggressive disease course.

Put N, Van Roosbroeck K, Konings P, Meeus P, Brusselmans C, Rack K, Gervais C, Nguyen-Khac F, Chapiro E, Radford-Weiss I, Struski S, Dastugue N, Gachard N, Lefebvre C, Barin C, Eclache V, Fert-Ferrer S, Laibe S, Mozziconacci MJ, Quilichini B, Poirel HA, Wlodarska I, Hagemeijer A, Moreau Y, Vandenberghe P, Michaux L; BCGHo and the GFCH.

Ann Hematol. 2012 Jun;91(6):863-73. doi: 10.1007/s00277-011-1393-y. Epub 2011 Dec 30.

PMID:
22205151
14.

A multicenter phase II trial of decitabine as first-line treatment for older patients with acute myeloid leukemia judged unfit for induction chemotherapy.

Lübbert M, Rüter BH, Claus R, Schmoor C, Schmid M, Germing U, Kuendgen A, Rethwisch V, Ganser A, Platzbecker U, Galm O, Brugger W, Heil G, Hackanson B, Deschler B, Döhner K, Hagemeijer A, Wijermans PW, Döhner H.

Haematologica. 2012 Mar;97(3):393-401. doi: 10.3324/haematol.2011.048231. Epub 2011 Nov 4.

15.

Low-dose decitabine versus best supportive care in elderly patients with intermediate- or high-risk myelodysplastic syndrome (MDS) ineligible for intensive chemotherapy: final results of the randomized phase III study of the European Organisation for Research and Treatment of Cancer Leukemia Group and the German MDS Study Group.

Lübbert M, Suciu S, Baila L, Rüter BH, Platzbecker U, Giagounidis A, Selleslag D, Labar B, Germing U, Salih HR, Beeldens F, Muus P, Pflüger KH, Coens C, Hagemeijer A, Eckart Schaefer H, Ganser A, Aul C, de Witte T, Wijermans PW.

J Clin Oncol. 2011 May 20;29(15):1987-96. doi: 10.1200/JCO.2010.30.9245. Epub 2011 Apr 11.

PMID:
21483003
16.

Interphase fluorescence in situ hybridization on selected plasma cells is superior in the detection of cytogenetic aberrations in plasma cell dyscrasia.

Put N, Lemmens H, Wlodarska I, Konings P, Moreau Y, Hagemeijer A, Vandenberghe P, Michaux L.

Genes Chromosomes Cancer. 2010 Nov;49(11):991-7. doi: 10.1002/gcc.20809.

PMID:
20662075
17.

Value of allogeneic versus autologous stem cell transplantation and chemotherapy in patients with myelodysplastic syndromes and secondary acute myeloid leukemia. Final results of a prospective randomized European Intergroup Trial.

de Witte T, Hagemeijer A, Suciu S, Belhabri A, Delforge M, Kobbe G, Selleslag D, Schouten HC, Ferrant A, Biersack H, Amadori S, Muus P, Jansen JH, Hellström-Lindberg E, Kovacsovics T, Wijermans P, Ossenkoppele G, Gratwohl A, Marie JP, Willemze R.

Haematologica. 2010 Oct;95(10):1754-61. doi: 10.3324/haematol.2009.019182. Epub 2010 May 21.

18.

The idic(X)(q13) in myeloid malignancies: breakpoint clustering in segmental duplications and association with TET2 mutations.

Paulsson K, Haferlach C, Fonatsch C, Hagemeijer A, Andersen MK, Slovak ML, Johansson B; MDS Foundation.

Hum Mol Genet. 2010 Apr 15;19(8):1507-14. doi: 10.1093/hmg/ddq024. Epub 2010 Jan 21.

PMID:
20093295
19.

ABL1 rearrangements in T-cell acute lymphoblastic leukemia.

Hagemeijer A, Graux C.

Genes Chromosomes Cancer. 2010 Apr;49(4):299-308. doi: 10.1002/gcc.20743. Review.

PMID:
20073070
21.

Improved detection of chromosomal abnormalities in chronic lymphocytic leukemia by conventional cytogenetics using CpG oligonucleotide and interleukin-2 stimulation: A Belgian multicentric study.

Put N, Konings P, Rack K, Jamar M, Van Roy N, Libouton JM, Vannuffel P, Sartenaer D, Ameye G, Speleman F, Herens C, Poirel HA, Moreau Y, Hagemeijer A, Vandenberghe P, Michaux L; Belgian Cytogenetic Group for Hemato-Oncology (BCGHO).

Genes Chromosomes Cancer. 2009 Oct;48(10):843-53. doi: 10.1002/gcc.20691.

PMID:
19582829
22.

Acquired mutations in TET2 are common in myelodysplastic syndromes.

Langemeijer SM, Kuiper RP, Berends M, Knops R, Aslanyan MG, Massop M, Stevens-Linders E, van Hoogen P, van Kessel AG, Raymakers RA, Kamping EJ, Verhoef GE, Verburgh E, Hagemeijer A, Vandenberghe P, de Witte T, van der Reijden BA, Jansen JH.

Nat Genet. 2009 Jul;41(7):838-42. doi: 10.1038/ng.391. Epub 2009 May 31.

PMID:
19483684
23.

Myeloid cell differentiation arrest by miR-125b-1 in myelodysplastic syndrome and acute myeloid leukemia with the t(2;11)(p21;q23) translocation.

Bousquet M, Quelen C, Rosati R, Mansat-De Mas V, La Starza R, Bastard C, Lippert E, Talmant P, Lafage-Pochitaloff M, Leroux D, Gervais C, Viguié F, Lai JL, Terre C, Beverlo B, Sambani C, Hagemeijer A, Marynen P, Delsol G, Dastugue N, Mecucci C, Brousset P.

J Exp Med. 2008 Oct 27;205(11):2499-506. doi: 10.1084/jem.20080285. Epub 2008 Oct 20.

24.

Heterogeneous patterns of amplification of the NUP214-ABL1 fusion gene in T-cell acute lymphoblastic leukemia.

Graux C, Stevens-Kroef M, Lafage M, Dastugue N, Harrison CJ, Mugneret F, Bahloula K, Struski S, Grégoire MJ, Nadal N, Lippert E, Taviaux S, Simons A, Kuiper RP, Moorman AV, Barber K, Bosly A, Michaux L, Vandenberghe P, Lahortiga I, De Keersmaecker K, Wlodarska I, Cools J, Hagemeijer A, Poirel HA; Groupe Francophone de Cytogénétique Hématologique; Belgian Cytogenetic Group for Hematology and Oncology.

Leukemia. 2009 Jan;23(1):125-33. doi: 10.1038/leu.2008.278. Epub 2008 Oct 16.

PMID:
18923437
25.

EVI1 overexpression in t(3;17) positive myeloid malignancies results from juxtaposition of EVI1 to the MSI2 locus at 17q22.

De Weer A, Speleman F, Cauwelier B, Van Roy N, Yigit N, Verhasselt B, De Moerloose B, Benoit Y, Noens L, Selleslag D, Lippert E, Struski S, Bastard C, De Paepe A, Vandenberghe P, Hagemeijer A, Dastugue N, Poppe B; Groupe Français de Cytogénétique Hématologique (GFCH).

Haematologica. 2008 Dec;93(12):1903-7. doi: 10.3324/haematol.13192. Epub 2008 Sep 24.

26.

Monosomal karyotype in acute myeloid leukemia: a better indicator of poor prognosis than a complex karyotype.

Breems DA, Van Putten WL, De Greef GE, Van Zelderen-Bhola SL, Gerssen-Schoorl KB, Mellink CH, Nieuwint A, Jotterand M, Hagemeijer A, Beverloo HB, Löwenberg B.

J Clin Oncol. 2008 Oct 10;26(29):4791-7. doi: 10.1200/JCO.2008.16.0259. Epub 2008 Aug 11.

PMID:
18695255
27.

Is there a difference in childhood T-cell acute lymphoblastic leukaemia and T-cell lymphoblastic lymphoma?

Uyttebroeck A, Vanhentenrijk V, Hagemeijer A, Boeckx N, Renard M, Wlodarska I, Vandenberghe P, Depaepe P, De Wolf-Peeters C.

Leuk Lymphoma. 2007 Sep;48(9):1745-54.

PMID:
17786710
28.

Chromosomal translocations independently predict treatment failure, treatment-free survival and overall survival in B-cell chronic lymphocytic leukemia patients treated with cladribine.

Van Den Neste E, Robin V, Francart J, Hagemeijer A, Stul M, Vandenberghe P, Delannoy A, Sonet A, Deneys V, Costantini S, Ferrant A, Robert A, Michaux L.

Leukemia. 2007 Aug;21(8):1715-22. Epub 2007 May 31.

PMID:
17541398
29.

Interstitial del(14)(q) involving IGH: a novel recurrent aberration in B-NHL.

Pospisilova H, Baens M, Michaux L, Stul M, Van Hummelen P, Van Loo P, Vermeesch J, Jarosova M, Zemanova Z, Michalova K, Van den Berghe I, Alexander HD, Hagemeijer A, Vandenberghe P, Cools J, De Wolf-Peeters C, Marynen P, Wlodarska I.

Leukemia. 2007 Sep;21(9):2079-83. Epub 2007 May 24. No abstract available.

PMID:
17525729
30.

Proposals for standardized protocols for cytogenetic analyses of acute leukemias, chronic lymphocytic leukemia, chronic myeloid leukemia, chronic myeloproliferative disorders, and myelodysplastic syndromes.

Haferlach C, Rieder H, Lillington DM, Dastugue N, Hagemeijer A, Harbott J, Stilgenbauer S, Knuutila S, Johansson B, Fonatsch C.

Genes Chromosomes Cancer. 2007 May;46(5):494-9.

PMID:
17311250
31.

A new disease categorization of low-grade myelodysplastic syndromes based on the expression of cytopenia and dysplasia in one versus more than one lineage improves on the WHO classification.

Verburgh E, Achten R, Louw VJ, Brusselmans C, Delforge M, Boogaerts M, Hagemeijer A, Vandenberghe P, Verhoef G.

Leukemia. 2007 Apr;21(4):668-77. Epub 2007 Feb 15.

PMID:
17301818
32.

Five members of the CEBP transcription factor family are targeted by recurrent IGH translocations in B-cell precursor acute lymphoblastic leukemia (BCP-ALL).

Akasaka T, Balasas T, Russell LJ, Sugimoto KJ, Majid A, Walewska R, Karran EL, Brown DG, Cain K, Harder L, Gesk S, Martin-Subero JI, Atherton MG, Brüggemann M, Calasanz MJ, Davies T, Haas OA, Hagemeijer A, Kempski H, Lessard M, Lillington DM, Moore S, Nguyen-Khac F, Radford-Weiss I, Schoch C, Struski S, Talley P, Welham MJ, Worley H, Strefford JC, Harrison CJ, Siebert R, Dyer MJ.

Blood. 2007 Apr 15;109(8):3451-61. Epub 2006 Dec 14.

33.

Screening for EVI1: ectopic expression absent in T-cell acute lymphoblastic leukemia patients and cell lines.

De Weer A, Poppe B, Cauwelier B, Van Roy N, Dastugue N, Hagemeijer A, De Paepe A, Speleman F.

Cancer Genet Cytogenet. 2006 Nov;171(1):79-80. No abstract available.

PMID:
17074597
34.

Clinical, cytogenetic and molecular characteristics of 14 T-ALL patients carrying the TCRbeta-HOXA rearrangement: a study of the Groupe Francophone de Cytogénétique Hématologique.

Cauwelier B, Cavé H, Gervais C, Lessard M, Barin C, Perot C, Van den Akker J, Mugneret F, Charrin C, Pagès MP, Grégoire MJ, Jonveaux P, Lafage-Pochitaloff M, Mozzicconacci MJ, Terré C, Luquet I, Cornillet-Lefebvre P, Laurence B, Plessis G, Lefebvre C, Leroux D, Antoine-Poirel H, Graux C, Mauvieux L, Heimann P, Chalas C, Clappier E, Verhasselt B, Benoit Y, Moerloose BD, Poppe B, Van Roy N, Keersmaecker KD, Cools J, Sigaux F, Soulier J, Hagemeijer A, Paepe AD, Dastugue N, Berger R, Speleman F.

Leukemia. 2007 Jan;21(1):121-8. Epub 2006 Oct 12.

PMID:
17039236
35.

Lipoblastoma and lipoblastomatosis.

Bourelle S, Viehweger E, Launay F, Quilichini B, Bouvier C, Hagemeijer A, Jouve JL, Bollini G.

J Pediatr Orthop B. 2006 Sep;15(5):356-61.

PMID:
16891964
36.

Cytogenetics and molecular genetics of T-cell acute lymphoblastic leukemia: from thymocyte to lymphoblast.

Graux C, Cools J, Michaux L, Vandenberghe P, Hagemeijer A.

Leukemia. 2006 Sep;20(9):1496-510. Epub 2006 Jul 6. Review.

PMID:
16826225
37.

Fusion of ETV6 to GOT1 in a case with myelodysplastic syndrome and t(10;12)(q24;p13).

Janssen H, Wlodarska I, Mecucci C, Hagemeijer A, Vandenberghe P, Marynen P, Cools J.

Haematologica. 2006 Jul;91(7):949-51. Epub 2006 Jun 1.

38.

[The practice guideline 'Diagnosis and pharmaceutical treatment of dementia'].

van Gool WA, Stam CJ, Steenhoek A, Hagemeijer A.

Ned Tijdschr Geneeskd. 2006 Apr 15;150(15):839-43. Dutch.

PMID:
16676513
39.

Molecular cytogenetic study of 126 unselected T-ALL cases reveals high incidence of TCRbeta locus rearrangements and putative new T-cell oncogenes.

Cauwelier B, Dastugue N, Cools J, Poppe B, Herens C, De Paepe A, Hagemeijer A, Speleman F.

Leukemia. 2006 Jul;20(7):1238-44. Epub 2006 May 4.

PMID:
16673021
40.

Coexistence of light chain disease and chronic lymphocytic leukaemia, a complex karyotype with a rapid fatal outcome.

Castryck H, van den Driessche M, Hagemeijer A, Stul M, Wynendaele W, Vandenberghe P, Moerman J.

Clin Lab Haematol. 2006 Apr;28(2):138-40.

PMID:
16630221
41.

KIT mutations and dose selection for imatinib in patients with advanced gastrointestinal stromal tumours.

Debiec-Rychter M, Sciot R, Le Cesne A, Schlemmer M, Hohenberger P, van Oosterom AT, Blay JY, Leyvraz S, Stul M, Casali PG, Zalcberg J, Verweij J, Van Glabbeke M, Hagemeijer A, Judson I; EORTC Soft Tissue and Bone Sarcoma Group; Italian Sarcoma Group; Australasian GastroIntestinal Trials Group.

Eur J Cancer. 2006 May;42(8):1093-103. Epub 2006 Apr 18.

PMID:
16624552
42.

Validation of an interphase fluorescence in situ hybridization approach for the detection of MLL gene rearrangements and of the MLL/AF9 fusion in acute myeloid leukemia.

Cavazzini F, Bardi A, Tammiso E, Ciccone M, Russo-Rossi A, Divona D, Lo Coco F, Hernandez JM, Wlodarska I, Hagemeijer A, Castoldi G, Cuneo A.

Haematologica. 2006 Mar;91(3):381-5. Epub 2006 Feb 17.

43.

MYC-containing double minutes in hematologic malignancies: evidence in favor of the episome model and exclusion of MYC as the target gene.

Storlazzi CT, Fioretos T, Surace C, Lonoce A, Mastrorilli A, Strömbeck B, D'Addabbo P, Iacovelli F, Minervini C, Aventin A, Dastugue N, Fonatsch C, Hagemeijer A, Jotterand M, Mühlematter D, Lafage-Pochitaloff M, Nguyen-Khac F, Schoch C, Slovak ML, Smith A, Solè F, Van Roy N, Johansson B, Rocchi M.

Hum Mol Genet. 2006 Mar 15;15(6):933-42. Epub 2006 Feb 1.

PMID:
16452126
44.

Acute megakaryoblastic leukemia and loss of the RUNX1 gene.

Berger R, Busson M, Dastugue N, Radford-Weiss I, Michaux L, Hagemeijer A, Quilichini B, Benattar L, Bernard O, Romana SP.

Cancer Genet Cytogenet. 2006 Jan 1;164(1):71-3.

PMID:
16364766
45.

EVI1 is consistently expressed as principal transcript in common and rare recurrent 3q26 rearrangements.

Poppe B, Dastugue N, Vandesompele J, Cauwelier B, De Smet B, Yigit N, De Paepe A, Cervera J, Recher C, De Mas V, Hagemeijer A, Speleman F.

Genes Chromosomes Cancer. 2006 Apr;45(4):349-56.

PMID:
16342172
46.

Activity and safety of combined rituximab with chlorambucil in patients with mantle cell lymphoma.

Bauwens D, Maerevoet M, Michaux L, Théate I, Hagemeijer A, Stul M, Danse E, Costantini S, Vannuffel P, Straetmans N, Vekemans MC, Deneys V, Ferrant A, Van Den Neste E.

Br J Haematol. 2005 Nov;131(3):338-40.

PMID:
16225653
47.

Deletion of the inositide-specific phospholipase c beta1 gene is a rare event in myelodysplastic syndrome and thus of limited value to predict leukemic progression.

Verburgh E, Verhoef G, Vandenberghe P, Hagemeijer A.

Leukemia. 2005 Nov;19(11):2011-3. No abstract available.

PMID:
16193086
48.

CIZ gene rearrangements in acute leukemia: report of a diagnostic FISH assay and clinical features of nine patients.

La Starza R, Aventin A, Crescenzi B, Gorello P, Specchia G, Cuneo A, Angioni A, Bilhou-Nabera C, Boqué C, Foà R, Uyttebroeck A, Talmant P, Cimino G, Martelli MF, Marynen P, Mecucci C, Hagemeijer A.

Leukemia. 2005 Sep;19(9):1696-9. No abstract available.

PMID:
15990865
49.

FOXP1, a gene highly expressed in a subset of diffuse large B-cell lymphoma, is recurrently targeted by genomic aberrations.

Wlodarska I, Veyt E, De Paepe P, Vandenberghe P, Nooijen P, Theate I, Michaux L, Sagaert X, Marynen P, Hagemeijer A, De Wolf-Peeters C.

Leukemia. 2005 Aug;19(8):1299-305.

PMID:
15944719
50.

CDKN2 deletions have no prognostic value in childhood precursor-B acute lymphoblastic leukaemia.

van Zutven LJ, van Drunen E, de Bont JM, Wattel MM, Den Boer ML, Pieters R, Hagemeijer A, Slater RM, Beverloo HB.

Leukemia. 2005 Jul;19(7):1281-4. No abstract available.

PMID:
15843818

Supplemental Content

Loading ...
Support Center